Introduction {#s1}
============

Renal biopsy is considered to be important for the diagnosis of renal involvement in patients with multiple myeloma (MM) because of the therapeutic and prognostic implications. Korbet and Schwartz \[[@b1]\] reviewed renal biopsy data on renal disease in MM patients, revealing that 40 -- 63% had myeloma cast nephropathy (MCN), 19 -- 26% had light chain deposition disease (LCDD), 7 -- 30% had amyloidosis, and less than 1% had cryoglobulinemic renal disease \[[@b1], [@b2]\]. According to these studies, renal pathology in patients with MM shows a single pattern. However, two patterns of renal disease occurring in the same patient have been reported by other authors. Lin et al. \[[@b3]\] reported a combination of MCN and LCDD in 11 patients, while Lorenz et al. \[[@b4]\] reported a 40-year-old woman whose renal biopsy revealed three concurrent pathologies, including MCN, amyloidosis, and LCDD. While MCN is the most common kidney disease associated with MM, it has also been reported to occur in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) \[[@b5], [@b6]\].

Because renal biopsy is invasive and carries a risk of bleeding, a noninvasive diagnostic method for renal disease associated with plasma cell dyscrasias is required. Albuminuria is a useful marker for glomerular involvement. Accordingly, this study was performed to determine whether the urinary albumin excretion rate (%UAE) could be used to distinguish pure MCN from MCN associated with glomerular lesions such as deposition of amyloid.

Materials and methods {#s2}
=====================

Patient selection {#sub-s1}
-----------------

Renal biopsy was performed in 2,284 patients at Toranomon Hospital from 2004 to 2014. Patients were excluded if they had monoclonal immunoglobulin deposition disease (MIDD) including LCDD, light and heavy chain deposition disease (LHCDD) and heavy chain deposition disease (HCDD), or if they had primary light chain (AL) and heavy chain (AH) amyloidosis, which did not fit the diagnostic criteria for MM \[[@b7]\] or LPL/WM \[[@b8]\]. 16 patients with a diagnosis of MCN were analyzed retrospectively. They were divided into a group that had pure MCN without glomerular amyloid deposition (group 1) and a group with CN plus glomerular amyloid deposition (group 2). This study was approved by the Institutional Review Board (IRB) of Toranomon Hospital, and the patients gave full written informed consent.

Histological evaluation {#sub-s2}
-----------------------

Renal biopsy specimens were processed for light microscopy (LM), immunofluorescence microscopy (IF), and electron microscopy (EM) according to the previously reported methods \[[@b9]\]. LM specimens were stained with hematoxylin and eosin (H & E), periodic acid Schiff (PAS), periodic acid methenamine silver (PAM), Masson trichrome (MT), and Congo red stain. IF was performed to detect immunoglobulin (Ig)G, IgA, IgM, κ light chain, and λ light chain as well as for complement components (C)1q, C3, and C4. Amyloid was diagnosed by detection of amorphous lesions showing Congo red positivity on LM that contained randomly-arranged fibrils 7 -- 12 nm in diameter on EM.

Tubular injury ratio (tubulointerstitial fibrosis and atrophy/the renal cortex) was classified into mild degree (\< 25%), moderate degree (25 -- 50%), and severe degree (\> 50%). Glomerular sclerotic ratio (global sclerotic glomeruli/total glomeruli × 100, %) was examined.

Laboratory tests {#sub-s3}
----------------

Blood and urine samples were collected from all patients before renal biopsy. Laboratory tests were performed to measure the hemoglobin (g/dL), white blood cell count (×10^4^/μL), platelet count (×10^4^/μl), total protein (TP) (g/dL), serum albumin (g/dL), serum creatinine (Cre) (mg/dL), serum adjusted calcium (a-Ca= serum calcium + 0.8 × (4 -- serum) albumin) (mg/dL), serum β2 microglobulin (β2MG), IgG (mg/dL), IgA (mg/dL), IgM (mg/dL), cryoglobulin, antinuclear antibody, 50% hemolytic complement (CH50) (normal range: 32 -- 47 U/mL), and estimated glomerular filtration rate (eGFR) (mL/min/1.73m^2^). By 24-hour urine collection, the total protein (g/day), urinary albumin excretion rate (%UAE= percentage of total urinary protein excreted as albumin), urinary free light chain excretion (FLC), and β2MG excretion (μg/day) were measured. In addition, the urine sediment was examined to determine the number of erythrocytes per high-power field (HPF) and other parameters. Serum monoclonal protein and urinary Bence-Jones protein were analyzed by protein electrophoresis and/or immunofixation electrophoresis.

Diagnosis of MM and LPL/WM {#sub-s4}
--------------------------

Diagnosis of MM was performed according to the criteria of the International Myeloma Working Group \[[@b7]\], and the Durie-Salmon (DS) staging system was employed to assess and classify MM \[[@b10]\]. LPS/WM was diagnosed on the basis of monoclonal IgM gammopathy and bone marrow involvement by LPL (characterized by low-grade B-cell malignancy composed of small lymphocytes and plasmacytoid lymphocytes) \[[@b8]\]. The M protein type was determined by serum and/or urine protein electrophoresis.

Diagnosis of myeloma cast nephropathy (MCN) {#sub-s5}
-------------------------------------------

MCN was diagnosed in MM or LPL/WM patients with renal dysfunction if renal biopsy revealed casts in the renal tubules that were pale or negative on PAS staining, eosinophilic on H & E staining, and polychromatic (red and blue) on MT staining. These tubular casts were restricted to either κ or λ light chain and were surrounded by inflammatory cells, including plasma cells and lymphoid cells \[[@b11]\].

Statistical analysis {#sub-s6}
--------------------

Data were compiled and analyzed by using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) \[[@b12]\]. Results were summarized as percentages, as the mean ± standard deviation \[SD\], or as the median and interquartile range (IQR), unless indicated otherwise.

Results {#s3}
=======

Case 1 (pure MCN) {#sub-s7}
-----------------

A 56-year-old Japanese woman was admitted to our hospital for evaluation of renal dysfunction with a serum Cre of 5.3 mg/dL and hypercalcemia (a-Ca: 13.5 mg/dL) ([Table 1](#Table1){ref-type="table"}, patient 7). Urinary protein excretion was 18.3 g daily, and urinary Bence Jones Protein (BJP)-κ was positive, while %UAE was only 0.9%. Bone marrow aspiration showed 58.0% κ-positive plasma cells, and MM was diagnosed (DS stage III A). A renal biopsy specimen was obtained, and LM revealed global sclerosis in 1 out of 19 glomeruli. While the glomeruli showed no significant abnormalities, tubular casts (eosinophilic on H & E staining, negative for PAS stain, polychromatic on MT staining, and positive for κ light chain) surrounded by inflammatory cells were detected ([Figure 1](#Figure1){ref-type="fig"}). Congo red stain was negative throughout the biopsy specimen, so pure MCN was diagnosed. She received three courses of vincristine-doxorubicin (adriamycin)-dexamethasone (VAD) therapy followed by high-dose melphalan (HDM) + autologous peripheral blood stem cell transplantation (SCT). Hematologic remission was not complete, so chemotherapy was continued, but the patient died of subdural hemorrhage 11 years and 2 months after the diagnosis.

Case 2 (CN plus AL amyloidosis) {#sub-s8}
-------------------------------

A 68-year-old Japanese man was admitted for evaluation of intestinal ileus ([Table 1](#Table1){ref-type="table"}, patient 13). Serum Cre was 1.1 mg/dL, and he had hypercalcemia (a-Ca: 11.8 mg/dL). Urinary protein excretion was 6.7 g daily, with both serum IgA-λ M protein and urinary BJP-λ being positive. %UAE was 59.3%. Bone marrow aspiration showed 31.6% λ-positive plasma cells, and MM was diagnosed (DS stage III-A). Examination of a renal biopsy specimen revealed no global sclerosis in 3 glomeruli on LM. The glomeruli contained Congo red-positive amorphous lesions, and subepithelial spicule formation was seen by PAM staining. In addition, EM revealed randomly-arranged fibrils of 7 -- 12 nm in diameter. Tubular casts surrounded by inflammatory cells were seen, which were negative for PAS, eosinophilic on H & E staining, polychromatic on MT staining, and positive for λ light chain ([Figure 2](#Figure2){ref-type="fig"}). Coexistence of MCN and light chain amyloidosis was diagnosed. Treatment with VAD + prednisolone was started, followed by 2 courses of thalidomide. However, remission was not achieved, and the patient died of pneumonia after 6 months.

Clinicopathological features of CN {#sub-s9}
----------------------------------

Clinicopathological features of the MCN patients are listed in [Table 1](#Table1){ref-type="table"}. The 16 patients consisted of 7 men and 9 women, with a mean (± SD) age of 60.8 ± 9.2 years.

Group 1 (pure MCN): BJP MM was the most common type in 6 patients (κ in 3 and λ in 3), followed by IgA-κ MM in 3 patients and IgD-λ MM in 1 patient. The D-S stage was I in 1 patient, II in 2 patients, and III in 7 patients.

Group 2 (MCN plus amyloid deposition): BJP-λ MM was diagnosed in 2 patients, while 2 patients had IgA-λ MM, and 2 patients had IgM-κ LPL/WM. Amyloid deposits were detected in the glomeruli of all 6 patients. While amyloid deposit was confirmed in the heart in 2 patients, in the stomach in 1 patient, in the large intestine in 3 patients, and in the nervous system in 1 patient.

In group 1, the chief complaints at diagnosis included bone pain (due to bone involvement by MM) in 6 patients, fatigue in 2 patients, and no symptoms (elevation of serum Cre) in 2 patients. In group 2, the chief symptoms were anasarca (due to severe albuminuria) in 5 patients and fatigue in 1 patient.

Histologically, group 1 included tubular injury associated with MCN of more than moderate degree in a total of 10 patients, and group 2 included tubular injury of mild degree in 4 patients out of 6 patients. Glomerular sclerotic ratio was not significantly different between the two groups.

Laboratory data {#sub-s10}
---------------

Laboratory data are compared between group 1 and group 2 in [Table 2](#Table2){ref-type="table"}. TP did not show a significant difference between the two groups, but serum albumin was significantly higher in group 1 than group 2 (p = 0.0101) (median (IQR) serum albumin was 3.68 (3.2 -- 4.3) vs. 2.45 (1.85 -- 3.3)). Serum a-Ca did not differ significantly between both groups. Serum Cre was significantly higher in group 1 compared with group 2 (p = 0.0343) (median (IQR) serum Cre was 4.29 (1.58 -- 4.85) vs. 0.96 (0.78 -- 4.28)). Although urinary protein did not show a significant difference between the two groups, %UAE was significantly lower in group 1 than group 2 (p = 0.00198) (median (IQR) %UAE was 3.55 (1.6 -- 6.25) vs. 64.6 (35.2 -- 74.00)). Urinary FLC (g/day) was significantly higher (p = 0.0146) in group 1 compared with group 2.

Treatment {#sub-s11}
---------

Treatment is summarized in [Table 1](#Table1){ref-type="table"}. In group 1, 5 patients received SCT after conditioning with VAD regimen and HDM. Thalidomide (Thal) was added in 3 patients, and melphalan prednisolone (MP) was added in 1 patient. MP only was given to 1 patient, while 1 patient received MP + VAD (4 cycles) + bortezomib (Bor) (3 cycles), 2 patients were given dexamethasone (DEX) + Bor, and 1 patient was treated with VAD (1 cycle) and MP (4 cycles).

In group 2, 1 patient received MP alone (6 cycles), 1 patient was treated with rituximab (RTX) + DEX (1 cycle) + cyclophosphamide + bortezomib + dexamethasone (CyBorD) (1 cycle), 1 patient was given VAD + Thal, 1 patient had VAD alone (2 cycles), 1 patient received RTX + DEX + CyBorD, and 1 patient was given SCT + RTX.

Outcome {#sub-s12}
-------

In group 1 (pure MCN), only 1 patient died (of unknown causes) less than 15 months after diagnosis. In group 2 (CN with amyloid deposition), 3 patients with MM died after less than 15 months, and 1 MM patient is alive after 28 months. The 2 patients with LPL/MW are alive after 32 months.

Discussion {#s4}
==========

In patients with MCN, tubular obstruction is caused by light chain casts, which form when monoclonal light chain production leads to high urinary excretion of free light chains that undergo coprecipitation with Tamm-Horsfall protein in the distal tubules \[[@b13]\].

Albuminuria is a useful indicator of glomerular disease. Leung et al. \[[@b14]\] compared %UAE among pure MCN (n = 43) with AL-amyloidosis (n = 177), LCDD (n = 28), and acute tubular necrosis (n = 12). In the patients with pure MCN, %UAE was significantly lower than in the patients with glomerular lesions (AL amyloidosis or LCDD), but they did not perform a comparison between pure MCN and MCN with amyloid deposition.

Nasr et al. \[[@b15]\] evaluated 190 patients with MM who underwent renal biopsy at the Mayo Clinic. The most common paraprotein-associated lesions were MCN (33%), monoclonal immunoglobulin deposition disease (22%), and amyloidosis (21%), while the main non-paraprotein-associated lesions were acute tubular necrosis (9%), hypertensive arteriosclerosis (6%), and diabetic nephropathy (5%). %UAE was highest in amyloidosis and lowest in MCN. Median survival from the diagnosis of MM was 44, 58, and 62 months in patients with MCN, amyloidosis, and monoclonal immunoglobulin deposition disease, respectively (p = 0.4) .

Although detection of MCN on renal biopsy is usually related to MM, CN has also been found in patients with LPL/WM. Perez et al. \[[@b5]\] reported a 76-year-old woman with LPL/WM who had monoclonal gammopathy (IgM-κ isotype) and cervical lymphadenopathy (biopsy showed monotonous proliferation of small lymphocytes with lymphoplasmacytoid differentiation). In this patient, renal biopsy showed evidence of light chain CN and the diagnosis was CN associated with LPL/WM. In addition, Gnemmi et al. \[[@b6]\] reported CN plus LCDD in 2 patients with LPL/WM.

In conclusion, we assessed the clinicopathological features and laboratory data of 16 patients with CN. %UAE may be a useful marker for the coexistence of glomerular amyloid deposition in patients with CN, which is important because coexisting amyloidosis seems to be related to a poor prognosis. In group 1 (pure MCN without amyloidosis), MM-related bone involvement may be the chief complication, and renal complications (tubulointerstitial MCN) may be detected at a later stage (eGFR: 19.5 mL/min/1.73 m^2^, CKD 4). In group 2 (MCN with amyloidosis), tubular damage was mild, and glomerular damage due to amyloid deposition could contribute to nephrotic range albuminuria and the occurrence of anasarca at an earlier stage of kidney disease (eGFR: 53.2 mL/min/1.73 m^2^, CKD 3A). Tubular injury associated with MCN might contribute to renal deterioration on group 1.

Limitation {#sub-s13}
----------

There are some limitations in this study. This was a small study. We could not discuss whether LPL/WM plus amyloidosis patients have a better prognosis than MM patients with amyloidosis, although LPL/WM patients with CN plus amyloidosis were shown to have better outcomes than MM patients with MCN plus amyloidosis because treatments used in this study might not be the most effective treatments for MM or amyloidosis and could result in inappropriate outcomes from suboptimal treatments.

%UAE of patient 10 in group 1 showed 14.9%, while %UAE of patient 11 in group 2 showed 13%. The difference of these 2 patients could not be differentiated. But the other 9 patients in group 1 showed %UAE less than 7.7%, and the other 5 patients in group 2 showed %UAE of more than 42.5%. This will indicate that patients with MCN with %UAE of more than 42.5% may have glomerular disease including amyloidosis, and MCN with %UAE less than 7.7% may become pure MCN. On the other hand, it is possible that %UAE may be the result of the severe renal impairment because there was a difference of renal function between group 1 and group 2. However, there is a report supporting our opinion. Leung et al. \[[@b14]\] reported that %UAE of MCN shows 7%, while %UAE of AL amyloid shows 70%.
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Table 1.Clinicopathological features of CN (both pure MCN and MCN+ amyloid deposition).GroupPatient NoAgeSexComplaintsDSsCre (mg/dL)UP (g/day)%UAEIgGIgAIgMSerum M proteinUrine M proteinAmyloidSclerotic glomeruli (%)Tubular injury ration (%)TreatmentFollow upOutcomeGroup 1 (pure CN)MM172FNo symptomDS II, ISS III1.555.460273.123.7NDBJP-λND21/46 (45)25 -- 50%MP^(3)^22Another hospital265FBone painDSIIIB1.55.35.863219.511.1NDBJP-κND2/25 (8)25 -- 50%MP^(1)^, VAD^(4)^, Bor^(3)^144Doing well376FBone painDSIIIB1.93.2155941.89.1NDBJP-λND10/28 (35.7)25 -- 50%DEX + Bor36Died of sepsis462FBone painDSIIIA2.210.63.160799.310.8BJP-κND2/16 (12.5)\> 50%VAD^(1)^, MP^(4)^1Another hospital547MNo symptomDSIIIB2.717.6548644.415.7IgA-λIgA-λND10/35 (28.6)\> 50%VAD3, SCT^(2)^, Thal142Doing well657MBone painDSIIIB4.66.5423111.78IgD-λBJP-λND2/42 (4.7)\> 50%VAD3, SCT^(2)^, Thal29Died of relapse of MM756FGeneral fatigueDSIIIB5.618.20.947228.78.5NDBJP-κND1/19 (5.2)\> 50%VAD3, SCT^(2)^, Thal125Died of subdural hemorrhage858MBone painDSIIIB12.18.551.8188463.35.4IgA-λBJP-λND0/10 (0.0)\> 50%17Died of relapse of MM953MBone painDSIB12.62.33.138936.610.8NDBJP-λND2/8 (25)\> 50%VAD, SCT^(2)^, MP96Another hospital1047MGeneral fatigueDSIIB13.1614.7371477.38.8IgA-λBJP-λND10/35 (28.6)\> 50%VAD3, SCT28Died of unknown causeGroup 2 (CN plus amyloid)MM1171FGeneral fatigueDSIIA0.72.7131.39745.946.5NDBJP-λK, H, S3/18 (16.7)\< 25%MP^(6)^15Died of amyloid1268FAnasarca0.83.8669.9531548.869.6IgA-λBJP-λK, S, I6/28 (21.7)\< 25%RTX + DEX, CyBorD32Doing well1368MAnasarcaDSIIIA1.16.759.35101.86012.1IgA-λBJP-λK, I0/3 (0.0)\< 25%VAD, Thal6Died of pneumonia1458FAnasarcaDSIII13.26.642.629710.49.4NDBJP-λK, H, I, N0/10 (0.0)\> 50%VAD^(2)^10 MDied of heart diseaseLPL/WM1577FAnasarca0.821.8575.9814123709.9IgM-κBJP-λK4/41 (9.8)\< 25%RTX + DEX, CyBorD43Doing well1663MAnasarca1.314.6473.34098.4791.5IgM-κBJP-λK11/34 (37.9)25 -- 50%SCT, RTX32Doing well[^1]

Table 2.Laboratory data of patients with pure MCN and MCN + amyloid deposition.Group12VariablesPure CN (n = 10)CN plus amyloid (n = 6)Significant differenceSex (M/F)M5/F5M2/F4Age57.6 (51.5 -- 68.7)68 (61.75 -- 72.5)0.082κ/λκ2/λ4κ3/λ7TP (g/dL)6.35 (5.9 -- 7.23)6.1 (4.85 -- 7.53)0.584Serum Alb (g/dL)3.68 (3.2 -- 4.3)2.45 (1.85 -- 3.3)0.0101Serum β 2MG (mg/L)7.15 (4.55--22.5)5.35 (2.73 -- 11.68)0.232BUN (mg/dL)29 (26 -- 41)18.5 (16 -- 36.5)0.0925Serum Cre (mg/dL)4.29 (1.58 -- 4.85)0.96 (0.78 -- 4.28)0.0343eGFR (mL/min/1.73m^2^)19.5 (10.4 -- 27.2)53.2 (33.7 -- 59.2)0.0312UA (mg/dL)7.35 (6.8 -- 7.98)7.15 (5.18 -- 9.33)0.704Serum a-Ca (mg/dL)9.55 (9.3 -- 11.3)10.45 (10.08 -- 10.98)0.158Hb (g/dL)8.35 (6.88 -- 11.1)11.3 (9.0 -- 12.45)0.212Urinary protein (g/day)5.65 (2.98 -- 9.06)4.25 (2.49 -- 6.62)0.492%UAE (%)3.55 (1.6 -- 6.25)64.6 (35.2 -- 74.00)0.00198Urinary FLC (g/day)4.55 (2.82 -- 8.02)1.5 (0.72 -- 2.48)0.0146Median (IQR)Median (IQR)

![Renal biopsy of case 1 (patient 7 in [Table 1](#Table1){ref-type="table"}). Light microscopy shows a tubular cast surrounded by inflammatory cells. The cast is eosinophilic on H & E staining (arrow), polychromatic (red and blue) on Masson trichrome staining (arrow), positive for κ light chain (arrow), and negative for λ light chain (arrow).](clinnephrol-92-081-01){#Figure1}

![Renal biopsy of case 2 (patient 13 in [Table 1](#Table1){ref-type="table"}). Light microscopy displays tubular casts surrounded by inflammatory cells. Casts are eosinophilic on H & E staining (arrow) and polychromatic (red and blue) on Masson trichrome staining (arrow). There is a Congo red-positive amorphous glomerular lesion (arrow). Periodic acid methenamine silver staining shows subepithelial spicule formation (arrow). Inset: EM shows randomly arranged fibrils measuring 7 -- 12 nm in diameter.](clinnephrol-92-081-02){#Figure2}

[^1]: MM = multiple myeloma; LPL/WM = lymphoplasmacytic lymphoma/Waldenström macroglobulinemia; MCN = myeloma cast nephropathy; K = kidney involvement; H = heart; S = stomach; I = large intestine; N = nerves; SCT = autologous peripheral blood stem cell transplantation; Dex = dexamethasone; Bor = bortezomib; Thal = thalidomide; CyBorD = cyclophosphamide + bortezomib + dexamethasone; ND = not detected. MP = melphalant prednisolone; VAD = vinchristine-doxurubicin(adriamycin)-dexamethasone; RTX = rituximab. ^(1)(2)(3)(4)(6)^ = Number of cycles.
